** Danske Bank downgrades Swedish medical technology firm
Arjo ARJOb.ST to "hold" from "buy" citing cost inflation and
supply chain issues
** Danske analyst Karl Norén says cost inflation is becoming
an issue, as the price increases to off-set this will lag a
couple of quarters
** He adds supply chain issues will lead to low organic
growth in Q1
** The broker cuts its price target by 19% to SEK 85, saying
the valuation is still quite high at EV/EBITDA 22x 2022, above
rival Getinge GETIb.ST which is currently performing better,
according to Danske
** Arjo shares are down 4.2% at 1148 GMT, after falling as
much as 9.1%
(Reporting by Agata Rybska)
((agata.rybska@thomsonreuters.com))